In subsequent years, other non-CAR approaches enhanced γδ T cell efficacy, such as inhibiting CD3ε for better tumor killing and using monoclonal antibodies against CTLA-4 and PD-1 to treat melanoma, yielding positive preclinical results. This evidence concerns the gene CD3E and neoplasm.